Pfizer final analysis of Phase 3 study indicates COVID-19 vaccine efficacy rate of 95%
Image Credit: Shortpedia
The Pfizer and BioNTech announced that after conducting the final efficacy analysis in the Phase 3 study, their COVID-19 vaccine met all of the study’s primary efficacy endpoints. They said that the analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection and also in participants with and without prior SARS-CoV-2 infection, in each case measured from 7 days after the second dose.